Core Insights - Idorsia Ltd presented new analyses of daridorexant for insomnia patients at World Sleep 2025, emphasizing its commitment to advancing sleep science [1][11] - The company highlighted the low abuse potential of daridorexant compared to other insomnia treatments, based on real-world data [3] - Daridorexant demonstrated efficacy in reducing wakefulness throughout the night, with significant improvements in sleep maintenance and daytime functioning [5][8] Efficacy and Safety of Daridorexant - A post-hoc analysis showed that daridorexant 50 mg effectively reduced wakefulness after sleep onset (WASO) in a dose-dependent manner, outperforming zolpidem in the second half of the night [5] - In women undergoing menopausal transition, daridorexant 50 mg improved sleep onset and maintenance without increasing next-morning sleepiness [6] - Patients with chronic insomnia and comorbid nocturia experienced improved sleep duration and reduced nocturia symptoms with daridorexant 50 mg, without adverse effects [8] Characterization of Insomnia Disorder - Analysis of over 5000 patients revealed that insomnia disorder negatively impacts both nighttime sleep and daytime functioning across various demographics [10] - The findings underscore the need for treatments that address the comprehensive burden of insomnia, improving both nocturnal and diurnal symptoms [10] Industry Context - World Sleep 2025 served as a platform for international collaboration among sleep professionals, focusing on advancements in sleep science and treatment [11] - Idorsia aims to challenge existing medical paradigms and develop transformative medicines, positioning itself as a leading biopharmaceutical company [12][13]